AUTHORS
Morgann Klink, Eric Chang2, Colin Carlock3, David Campbell4, Pan Pan, PhD5, Corinne Cayatte, PhD6, Arthur L Shaffer III, PhD7, Jamal Saeh8, Elaine Hurt9, Puja Sapra10
AFFILIATIONS
1 AstraZeneca, Gaithersburg, Maryland, United States
2 AstraZeneca, Gaithersburg, Maryland, United States
3 AstraZeneca, Gaithersburg, Maryland, United States
4 AstraZeneca, Gaithersburg, Maryland, United States
5 AstraZeneca, Gaithersburg, Maryland, United States
6 AstraZeneca, Gaithersburg, Maryland, United States
7 AstraZeneca, Gaithersburg, Maryland, United States
8 AstraZeneca, Gaithersburg, Maryland, United States
9 AstraZeneca, Gaithersburg, Maryland, United States
10 AstraZeneca, Gaithersburg, Maryland, United States
ABSTRACT
Multiple myeloma (MM) is an aggressive hematologic malignancy with a high relapse rate. While B-cell maturation antigen (BCMA) is highly expressed on malignant plasma cells, therapies targeting additional surface markers have been developed. G protein-coupled receptor class C group 5 member D (GPRC5D) is expressed in MM with little expression in normal hematopoietic immune cells other than plasma cells. Current targeted therapies for MM predominantly focus on BCMA, including antibody-drug conjugate (ADC), T cell engagers (TCEs) and CAR-T cells to enhance T cell-mediated cytotoxicity. Bispecific antibodies targeting GPRC5D or both antigens also demonstrated striking efficacy in the patient population with relapsed/refractory (R/R) MM. However, given the heterogenous expression of tumor-associated antigens and the T-cell fitness, there is still significant unmet need to develop combinational therapies for R/R MM patients.
This study evaluated the sequential combination of two distinct agents in preclinical mouse models. Vemzatatug vedotin (vemza-ve, AZD0305) is a first-in-class GPRC5D-MMAE ADC with a drug-to-antibody ratio (DAR) of 4. Vemza-ve is currently in Phase I clinical development (NCT06106945). Elranatamab is an approved BCMA-directed bispecific antibody for patients with R/R MM who have received at least 4 prior lines of treatment. Mechanistically, vemza-ve provides a direct anti-tumor killing by targeted delivery of a cytotoxic MMAE payload which induces microtubule inhibition and cell death, while elranatamab targets BCMA and T cells through the formation of an immune synapse eradicating MM cells.
Sequential dosing of vemza-ve followed by elranatamab biosimilar was tested in human pan-T cell-engrafted MM xenograft models. Activated pan-T cells derived from healthy donor PBMCs were expanded in culture for in vivo engraftment. Mice were subcutaneously implanted with MOLP-2 or MM1.R myeloma cells and given a single intravenous administration of vemza-ve. Activated pan-T cells were subsequently engrafted 2 days prior to weekly treatments of elranatamab biosimilar. The combination of vemza-ve and elranatamab biosimilar was well tolerated with no significant body weight loss observed in mice. This combination therapy resulted in robust tumor growth inhibition (TGI) in the MOLP-2 model with a TGI of 94.9% in comparison with a TGI of 59.6% and 49.4% in vemza-ve alone and elranatamab biosimilar alone groups, respectively. Similar results were observed in an additional MOLP-2 study using a different pan-T donor. In the more aggressive MM1.R model, combination treatment sustained tumor growth control at a longer duration than monotherapy groups. These findings demonstrate the combinable anti-tumor activity of vemza-ve and elranatamab, supporting the current clinical development of this strategy for treating R/R MM.
DISCLOSURES
Pan Pan, PhD: AstraZeneca - Current equity holder in publicly-traded company; AstraZeneca - Current Employment